Bristol-Myers Squibb Company (BMY - Free Report) will reacquire the rights to ASLAN002 (BMS777607) from privately held biotech company, Aslan Pharmaceuticals, as announced by the latter. Reacquired rights cover the territories of China, Australia, Korea, Taiwan and other Asian countries.
Aslan, an oncology-focused company, had in-licensed marketing rights to ASLAN002 from Bristol-Myers in Nov 2011 in the aforementioned countries. ASLAN002 is a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. The candidate was being developed for the treatment of solid tumors. Results from a phase I study on the candidate showed that it was safe and well tolerated.
Data from the phase I study showed that the inhibition of RON resulted in the potent inhibition of plasma biomarkers of RON activity.
As a result, Bristol-Myers will pay an upfront payment of $10 million to Aslan. Further, the latter is entitled to receive development and regulatory milestones in excess of $50 million, along with royalty payments on future worldwide sales of ASLAN002. On the other hand, Bristol-Myers will assume the responsibility for all development and commercialization activities and expenses related to the candidate hereafter.
The reacquisition of rights will strengthen Bristol-Myers’ oncology pipeline. We note that the company boasts a robust pipeline across a wide range of core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, and virology among others. The company’s key oncology products include Opdivo, Sprycel, Yervoy and the recently launched Empliciti. Beyond oncology, the company remains focused on immunology and cardiovascular drugs like Orencia and Eliquis.
Investors interested in the healthcare sector can consider stocks like Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Bristol-Myers Squibb Company (BMY - Free Report) will reacquire the rights to ASLAN002 (BMS777607) from privately held biotech company, Aslan Pharmaceuticals, as announced by the latter. Reacquired rights cover the territories of China, Australia, Korea, Taiwan and other Asian countries.
Aslan, an oncology-focused company, had in-licensed marketing rights to ASLAN002 from Bristol-Myers in Nov 2011 in the aforementioned countries. ASLAN002 is a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. The candidate was being developed for the treatment of solid tumors. Results from a phase I study on the candidate showed that it was safe and well tolerated.
Data from the phase I study showed that the inhibition of RON resulted in the potent inhibition of plasma biomarkers of RON activity.
As a result, Bristol-Myers will pay an upfront payment of $10 million to Aslan. Further, the latter is entitled to receive development and regulatory milestones in excess of $50 million, along with royalty payments on future worldwide sales of ASLAN002. On the other hand, Bristol-Myers will assume the responsibility for all development and commercialization activities and expenses related to the candidate hereafter.
The reacquisition of rights will strengthen Bristol-Myers’ oncology pipeline. We note that the company boasts a robust pipeline across a wide range of core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, and virology among others. The company’s key oncology products include Opdivo, Sprycel, Yervoy and the recently launched Empliciti. Beyond oncology, the company remains focused on immunology and cardiovascular drugs like Orencia and Eliquis.
Investors interested in the healthcare sector can consider stocks like Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on PCRX - FREE
Get the latest research report on CORT - FREE
Get the latest research report on ANIP - FREE